See All Slides - tctmd.com

Slides

Presentation TCT 2012

Case 2: FFR and Multivessel Disease

Presenter: Pim Tonino

October 25, 2012

Presentation TCT 2012

TWENTE 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents

Presenter: Clemens von Birgelen

October 25, 2012

Presentation TCT 2012

IVUS-Guided PCI: From Stent Sizing to Predicting Thrombosis and Restenosis

Presenter: Gary Mintz

October 25, 2012

Presentation TCT 2012

Session and Participant Introduction

Presenter: Anthony Gershlick

October 25, 2012

$Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!$

Presentation TCT 2012

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Gilles Montalescot

October 25, 2012

Presentation TCT 2012

Dynamic Obstruction: Mechanisms and Implications for Treatment

Presenter: Carey Kimmelstiel

October 25, 2012

Presentation TCT 2012

DCB Cost-Effectiveness Analysis: What Results Must Be Seen for Success in the United States?

Presenter: Duane Pinto

October 25, 2012

Presentation TCT 2012

Against: Patients Benefit from Cooling Off with Pharmacological Stabilization!

Presenter: Anthony Gershlick

October 25, 2012

Presentation TCT 2012

Case Study(6)

Presenter: H. Robert Superko

October 25, 2012

Presentation TCT 2012

Debate: Transradial Access Should Be the Default Access Site in STEMI Patients!

Presenter: Jennifer Tremmel

October 25, 2012

Advertisement

Slides

Case 2: FFR and Multivessel Disease

TWENTE 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents

IVUS-Guided PCI: From Stent Sizing to Predicting Thrombosis and Restenosis

Session and Participant Introduction

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Dynamic Obstruction: Mechanisms and Implications for Treatment

DCB Cost-Effectiveness Analysis: What Results Must Be Seen for Success in the United States?

Against: Patients Benefit from Cooling Off with Pharmacological Stabilization!

Case Study(6)

Debate: Transradial Access Should Be the Default Access Site in STEMI Patients!

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content